Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course

about

Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course

Item

http://www.wikidata.org/entity/Q58040795

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Prognostic value of routinely ...... es during their disease course

@en

Prognostic value of routinely ...... es during their disease course

@nl

type

Item

label

Prognostic value of routinely ...... es during their disease course

@en

Prognostic value of routinely ...... es during their disease course

@nl

prefLabel

Prognostic value of routinely ...... es during their disease course

@en

Prognostic value of routinely ...... es during their disease course

@nl

P1476

Prognostic value of routinely ...... es during their disease course

@en

P2093

Ahmad Sajadieh

http://www.w3.org/2001/XMLSchema#string

Erik Kjøller

http://www.w3.org/2001/XMLSchema#string

Gorm Jensen

http://www.w3.org/2001/XMLSchema#string

Hans Jørn Kolmos

http://www.w3.org/2001/XMLSchema#string

Jens Kastrup

http://www.w3.org/2001/XMLSchema#string

Jørgen Hilden

http://www.w3.org/2001/XMLSchema#string

Per Winkel

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry.

Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease

Index event bias as an explanation for the paradoxes of recurrence risk research.

Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

Two criteria for evaluating risk prediction models

Estimating glomerular filtration rate from serum creatinine and cystatin C.

25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study.

Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease.

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Fai

P304

e000808

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/OPENHRT-2018-000808

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30228904

http://www.w3.org/2001/XMLSchema#string

P932

6135459

http://www.w3.org/2001/XMLSchema#string